학술논문
Multisite study of the relationships between antemortem [11C]PIB‐PET Centiloid values and postmortem measures of Alzheimer's disease neuropathology
Document Type
article
Author
La Joie, Renaud; Ayakta, Nagehan; Seeley, William W; Borys, Ewa; Boxer, Adam L; DeCarli, Charles; Doré, Vincent; Grinberg, Lea T; Huang, Eric; Hwang, Ji‐Hye; Ikonomovic, Milos D; Jack, Clifford; Jagust, William J; Jin, Lee‐Way; Klunk, William E; Kofler, Julia; Lesman‐Segev, Orit H; Lockhart, Samuel N; Lowe, Val J; Masters, Colin L; Mathis, Chester A; McLean, Catriona L; Miller, Bruce L; Mungas, Daniel; O'Neil, James P; Olichney, John M; Parisi, Joseph E; Petersen, Ronald C; Rosen, Howard J; Rowe, Christopher C; Spina, Salvatore; Vemuri, Prashanthi; Villemagne, Victor L; Murray, Melissa E; Rabinovici, Gil D
Source
Alzheimer's & Dementia. 15(2)
Subject
Language
Abstract
IntroductionWe sought to establish the relationships between standard postmortem measures of AD neuropathology and antemortem [11C]PIB-positron emission tomography ([11C]PIB-PET) analyzed with the Centiloid (CL) method, a standardized scale for Aβ-PET quantification.MethodsFour centers contributed 179 participants encompassing a broad range of clinical diagnoses, PET data, and autopsy findings.ResultsCL values increased with each CERAD neuritic plaque score increment (median -3 CL for no plaques and 92 CL for frequent plaques) and nonlinearly with Thal Aβ phases (increases were detected starting at phase 2) with overlap between scores/phases. PET-pathology associations were comparable across sites and unchanged when restricting the analyses to the 56 patients who died within 2 years of PET. A threshold of 12.2 CL detected CERAD moderate-to-frequent neuritic plaques (area under the curve = 0.910, sensitivity = 89.2%, specificity = 86.4%), whereas 24.4 CL identified intermediate-to-high AD neuropathological changes (area under the curve = 0.894, sensitivity = 84.1%, specificity = 87.9%).DiscussionOur study demonstrated the robustness of a multisite Centiloid [11C]PIB-PET study and established a range of pathology-based CL thresholds.